Holak TA - Search Results

1

Rapid and efficient hydrophilicity tuning of p53/mdm2 antagonists.

Srivastava S, Beck B, Wang W, Czarna A, Holak TA, Dömling A. Srivastava S, et al. Among authors: holak ta. J Comb Chem. 2009 Jul-Aug;11(4):631-9. doi: 10.1021/cc9000218. J Comb Chem. 2009. PMID: 19548636 Free PMC article.

2

Molecular basis for the inhibition of p53 by Mdmx.

Popowicz GM, Czarna A, Rothweiler U, Szwagierczak A, Krajewski M, Weber L, Holak TA. Popowicz GM, et al. Among authors: holak ta. Cell Cycle. 2007 Oct 1;6(19):2386-92. doi: 10.4161/cc.6.19.4740. Epub 2007 Oct 12. Cell Cycle. 2007. PMID: 17938582

3

Isoquinolin-1-one inhibitors of the MDM2-p53 interaction.

Rothweiler U, Czarna A, Krajewski M, Ciombor J, Kalinski C, Khazak V, Ross G, Skobeleva N, Weber L, Holak TA. Rothweiler U, et al. Among authors: holak ta. ChemMedChem. 2008 Jul;3(7):1118-28. doi: 10.1002/cmdc.200800025. ChemMedChem. 2008. PMID: 18428185

4

Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.

Popowicz GM, Czarna A, Holak TA. Popowicz GM, et al. Among authors: holak ta. Cell Cycle. 2008 Aug;7(15):2441-3. doi: 10.4161/cc.6365. Epub 2008 May 27. Cell Cycle. 2008. PMID: 18677113

5

NMR screening for lead compounds using tryptophan-mutated proteins.

Rothweiler U, Czarna A, Weber L, Popowicz GM, Brongel K, Kowalska K, Orth M, Stemmann O, Holak TA. Rothweiler U, et al. Among authors: holak ta. J Med Chem. 2008 Aug 28;51(16):5035-42. doi: 10.1021/jm8002813. Epub 2008 Aug 5. J Med Chem. 2008. PMID: 18680271

6

High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.

Czarna A, Popowicz GM, Pecak A, Wolf S, Dubin G, Holak TA. Czarna A, et al. Among authors: holak ta. Cell Cycle. 2009 Apr 15;8(8):1176-84. doi: 10.4161/cc.8.8.8185. Epub 2009 Apr 16. Cell Cycle. 2009. PMID: 19305137

7

Robust NMR screening for lead compounds using tryptophan-containing proteins.

Bista M, Kowalska K, Janczyk W, Dömling A, Holak TA. Bista M, et al. Among authors: holak ta. J Am Chem Soc. 2009 Jun 10;131(22):7500-1. doi: 10.1021/ja901863h. J Am Chem Soc. 2009. PMID: 19422216

8

Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery.

Popowicz GM, Czarna A, Wolf S, Wang K, Wang W, Dömling A, Holak TA. Popowicz GM, et al. Among authors: holak ta. Cell Cycle. 2010 Mar 15;9(6):1104-11. doi: 10.4161/cc.9.6.10956. Epub 2010 Mar 15. Cell Cycle. 2010. PMID: 20237429

9

1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity.

Huang Y, Wolf S, Bista M, Meireles L, Camacho C, Holak TA, Dömling A. Huang Y, et al. Among authors: holak ta. Chem Biol Drug Des. 2010 Aug;76(2):116-29. doi: 10.1111/j.1747-0285.2010.00989.x. Epub 2010 May 18. Chem Biol Drug Des. 2010. PMID: 20492448 Free PMC article.

10

Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

Czarna A, Beck B, Srivastava S, Popowicz GM, Wolf S, Huang Y, Bista M, Holak TA, Dömling A. Czarna A, et al. Among authors: holak ta. Angew Chem Int Ed Engl. 2010 Jul 19;49(31):5352-6. doi: 10.1002/anie.201001343. Angew Chem Int Ed Engl. 2010. PMID: 20575124 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

204 results

Search Page

Filters